Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Galaxy Biomedical Investment Co., Ltd. operates in the transmission and distribution, electronic information, and bio-pharmaceutical industries in China. The company produces and sells various transformer products, such as power, rectifier, and special transformers for use in metal smelting, electrochemistry, and power grid companies; and manufactures and sells electronic components, including displacement sensors, brake resistance boxes, radio frequency components, resistors, potentiometers, and others for use in aviation, aerospace, weapons, ships, AI intelligence, new energy, rail transit, communications, smart grids, instrumentation and other fields. It also offers animal products, and monoclonal antibody and targeted drugs, as well as drugs for the treatment of cancer and other diseases; laboratory equipment; and CRO, CAR-T technology and stem cell technology research and development, malignant cancer immune cell technology, and genetic testing services. The company also exports its products. The company was formerly known as Beihai Yinhe Industry Investment Co., Ltd. and changed its name to Galaxy Biomedical Investment Co., Ltd. in October 2015. Galaxy Biomedical Investment Co., Ltd. was founded in 1993 and is headquartered in Beihai, China.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral o
Buy
Sell